Skip to content

Workplace Intervention: Activity Monitoring as a Tool for Corporate Wellness and Weight Loss

Workplace Intervention: Activity Monitoring as a Tool for Corporate Wellness and Weight Loss

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01461382
Enrollment
36
Registered
2011-10-28
Start date
2008-05-31
Completion date
2009-12-31
Last updated
2011-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Brief summary

Is a one-year intervention with Treadmill Desks associated with increased employee daily physical activity and decreased sedentariness. 36 employees with sedentary jobs (87 + 27 kg, BMI 29 + 7 kg/m2) used a Treadmill Desk for one year. Daily Physical Activity, work performance, body composition, and blood variables were measured at Baseline and 6 and 12 months after the Treadmill Desk intervention.

Interventions

OTHERTreadmill Desks

Treadmill Desk were installed in subjects personal workspace.

Sponsors

Mayo Clinic
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Subjects will be recruited regardless of race/ethnicity.

Exclusion criteria

* Definite termination criteria. * Request by subject to leave study. * Evidence of deliberate non-compliance (e.g.; placing activity instruments on another individual, deliberate destruction of instruments). * Pregnancy. * Alcohol abuse; elicit drug abuse. * Development of chronic condition that is likely to impact on metabolic variables or requiring medications likely to impact on metabolic variables or likely to result in subject being unable to participate (e.g., Grave's disease, hypothyroidism, rheumatoid arthritis requiring steroids or limiting mobility, congestive cardiac failure, neurological disorder such as multiple sclerosis or stroke). * Development of acute condition that is likely to impact on metabolic variables or requiring medications likely to impact on metabolic variables or likely to result in subject being unable to participate (e.g., motor vehicle accident with multiple fractures, myocardial infarction, major depression). Potential termination criteria. Development of acute or chronic condition that may impact on metabolic variables or requiring medications likely to impact on metabolic variables or likely to result in subject being unable to participate. Subjects will be reviewed on a subject-by-subject basis and will be reported to the Safety-Monitoring Panel. Specific action plans are pre-assigned for: * Diabetes (two fasting plasma glucose values \>126 mg/dl). Here, glycosylated hemoglobin will be measured three monthly (by the study) and subjects referred to their local physician for preventative screening. Subjects will be excluded from further study with any glycosylated hemoglobin value of \>8% or symptomatic hyperglycemia. * Depression or low mood. Here, all patients will be asked to be evaluated by their primary care physician and if appropriate referred to a psychiatrist. The opinion of the psychiatrist will be used to determine continuance or termination in the protocol. This does not represent a comprehensive listing of criteria or causes. All subjects who withdraw or whom are withdrawn from the study or whom are considering/being considered for withdrawal will be referred to the Safety-Monitoring Panel. These subjects' data will be scrutinized (whether terminated or not) separately to assess for association of intervention with a specific adverse outcome.

Design outcomes

Primary

MeasureTime frameDescription
Daily Physical Activity1 yearMeasured for all waking hours using tri-axial accelerometry.

Secondary

MeasureTime frame
Body Weightbaseline, 6 months, 12 months
Body Compositionbaseline, 6 months, 12 months
Venous bloodbaseline, 6 months, 12 months
Work performancebaseline, 6 months, 12 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026